Thanks for joining us in Year 1 of Bio.News. We published over 700 stories in less than one year – and these were the most popular. Happy Holiday Reading!
When the monkeypox (now mpox) outbreak began, the biotech industry was already ahead of the game, thanks to U.S. government investment in vaccines and antivirals to use against potential bioweapons. Bio.News got an exclusive interview with Phillip Gomez, CEO of SIGA Technologies, Inc., which makes TPOXX (tecovirimat), an antiviral used against monkeypox.
More than 30 years after he was diagnosed with HIV, a 66-year-old patient was in full remission after receiving a stem cell transplant meant to treat his leukemia – making him the oldest HIV patient cured, a feat for biotech innovation.
Sree Kant, Founder and CEO of BAKX Therapeutics, makes the case for founder-CEOs as change agents and drivers of innovation in an opinion piece exclusive to Bio.News.
Mike Huckman, a member of the BIO Board of Directors, Emerging Companies Section, and Global Practice Leader, Executive Communications, at Real Chemistry, explains what the biotech industry needs to do to help combat misinformation, in an opinion piece exclusive to Bio.News.
BIO member companies attended the launch of President Biden’s executive order on biotechnology and biomanufacturing at the White House – here’s what they said.
An economic impact report (by World Perspectives Inc. for CropLife International) shows Mexico’s looming ban on GM corn will harm economies on both sides of the U.S.-Mexican border and worsen food security for Mexico’s citizens just as inflation and strained supply chains are impacting consumers around the world.
To get a better sense of how companies in the biotechnology sector are recruiting in this unique market, Bio.News interviewed Travere Therapeutics’ Senior Director of Talent Acquisition, Amy Hernandez, to discuss how the BIO member company is attracting top talent.
Burkholderia pseudomallei is typically endemic to much warmer climates, but with the rapid rate of climate change, the landscape of bacterial infection is changing in the U.S. Like this particular bacteria on the Gulf Coast, diseases once unseen in the U.S now thrive. And with the growing antimicrobial resistance, this bacteria won’t be the last.
Back in September, we took a deep dive into the 340B program and how it’s hurting patients.
Our exclusive look at how BIO Ventures for Global Health (BVGH) worked with local partners to make the NSIA-LUTH Cancer Center (NLCC) in Lagos, Nigeria, one of the most effective and impactful cancer centers in Africa.
The European Health Data Space (EHDS) will change how patients, doctors, researchers, and policymakers access and use health data, and also affect companies operating in – or about to enter – the EU, writes Leander Vranken, Digital Health Policy Officer at the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), in a Bio.News exclusive.
One of our top stories from the BIO International Convention in 2022, we explored the next frontier of medicine: microbiome therapeutics.
Developed by Amylyx Pharmaceuticals, the drug was partially funded by the viral social media campaign in which participants dumped buckets of ice water over their heads to raise awareness and money for the ALS Association.
Bio.News was the exclusive media at the BIO Patient and Health Advocacy Summit in 2022 – read the kick-off with remarks from Paul Hastings, CEO at Nkarta Therapeutics and Chair of BIO’s Board, and BIO’s interim CEO with Rachel King.